PLX

Protalix BioTherapeutics Announces Oral GCD Data to be Presented at WORLD Symposium 2014

[GlobeNewswire] – CARMIEL, Israel — Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) announced today that phase I clinical trial data for oral GCD (PRX-112) for the treatment of Gaucher disease will be presented by Professor … moreView todays social media effects on PLXView the latest stocks trending across Twitter. Click to view dashboardSee who Protalix is hiring next, click here to view […]

Protalix BioTherapeutics Treats First Gaucher Patient in Phase I Study With PRX-112, an Orally-Administered Enzyme Treatment of Gaucher Disease

[at noodls] – CARMIEL, Israel, April 2, 2013 (GLOBE NEWSWIRE) — Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that the first patient has been treated in the Company’s phase I clinical trial … moreView todays social media effects on PLXView the latest stocks trending across Twitter. Click to view dashboardSee who Protalix is hiring next, click here to view […]

UPLYSO(TM) (alfataliglicerase) Approved in Brazil by ANVISA for the Treatment of Gaucher Disease

[at noodls] – NEW YORK and CARMIEL, Israel, March 18, 2013 (GLOBE NEWSWIRE) — Pfizer Inc. (NYSE:PFE) and Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX) announced today that the Brazilian National Health Surveillance … moreView todays social media effects on PLXView the latest stocks trending across Twitter. Click to view dashboardSee who Protalix is hiring next, click here to view […]

Protalix BioTherapeutics Reviewing Partnering and Other Alternatives

[at noodls] – CARMIEL, Israel, Feb. 5, 2013 (GLOBE NEWSWIRE) — Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX) (TASE:PLX), confirms, in response to inquiries received this morning and a report appearing in the Israeli … moreView todays social media effects on PLXView the latest stocks trending across Twitter. Click to view dashboardSee who Protalix is hiring next, click here to view […]

Protalix BioTherapeutics Announces New Clinical Data on Taliglucerase Alfa to be Presented at the WORLD Lysosomal Disease Network Symposium

[at noodls] – CARMIEL, Israel, Jan. 31, 2013 (GLOBE NEWSWIRE) — Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX) (TASE:PLX), announced today that new clinical data on taliglucerase alfa will be presented at the 9th Annual … moreView todays social media effects on PLXView the latest stocks trending across Twitter. Click to view dashboardSee who Protalix is hiring next, click here to view […]

Protalix BioTherapeutics Announces First Patient Treated in Phase I/II Study of Fabry Patients With PRX-102

[at noodls] – CARMIEL, Israel, Dec. 10, 2012 (GLOBE NEWSWIRE) — Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX) (TASE:PLX), announced today that the first patient has been treated in the Company’s phase I/II clinical … moreView todays social media effects on PLXView the latest stocks trending across Twitter. Click to view dashboardSee who Protalix is hiring next, click here to view […]